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Toll-like receptor triggering and T-cell costimulation induce
potent antitumor immunity in mice
Abstract
PURPOSE: To determine the antitumor activity of a novel combination of two immunomodulatory
agents that simultaneously direct multiple components of immunity against cancer. EXPERIMENTAL
DESIGN: We combined the Toll-like receptor agonist CpG 1826 with a T-cell costimulatory antibody
specific for CD137 in an optimal treatment route and dosing schedule against established tumors in two
mouse models. Mechanistic insight was gained using gene-deficient mice and cell-depleting antibodies.
RESULTS: The combination was shown to eradicate tumors in a large proportion of mice. Crucial roles
for CD8(+) T cells, natural killer cells, and IFNs were shown. CpG and anti-CD137 injection led to
activation of dendritic cells and optimal expansion of activated T cells in the blood. Macrophages were
not necessary for therapeutic effect, and indeed depletion of macrophages in vivo enhanced therapy
leading to tumor rejection in 100% of mice, which has not been previously reported in the
immunotherapeutic setting. Long-term surviving mice were resistant to tumor rechallenge,
demonstrating immunologic memory. In addition, we show, for the first time, that mice lacking B cells
have a total loss of a recall response against tumor, suggesting a role for B cells in the induction of
antitumor immunologic memory. CONCLUSION: This study provides support for the use of a novel
combination of immunomodulatory agents stimulating multiple facets of immunity for the effective
immunotherapy of cancer. (Clin Cancer Res 2009;15(24):7624-33).
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Clinulatory agents that simultaneouslydirectmultiple components of immunity against cancer.
Experimental Design: We combined the Toll-like receptor agonist CpG 1826 with a T-
cell costimulatory antibody specific for CD137 in an optimal treatment route and dosing
schedule against established tumors in two mouse models. Mechanistic insight was
gained using gene-deficient mice and cell-depleting antibodies.
Results: The combination was shown to eradicate tumors in a large proportion of mice.
Crucial roles for CD8+ T cells, natural killer cells, and IFNs were shown. CpG and anti-
CD137 injection led to activation of dendritic cells and optimal expansion of activated T
cells in the blood. Macrophages were not necessary for therapeutic effect, and indeed
depletion of macrophages in vivo enhanced therapy leading to tumor rejection in 100%
of mice, which has not been previously reported in the immunotherapeutic setting.
Long-term surviving mice were resistant to tumor rechallenge, demonstrating immu-
nologic memory. In addition, we show, for the first time, that mice lacking B cells have a
total loss of a recall response against tumor, suggesting a role for B cells in the induc-
tion of antitumor immunologic memory.
Conclusion: This study provides support for the use of a novel combination of immu-
nomodulatory agents stimulating multiple facets of immunity for the effective immu-
notherapy of cancer. (Clin Cancer Res 2009;15(24):7624–33)An effective immune response against disease requires the co-
ordinated action of several components of the immune system.
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7624Cancer Res 2009;15(24) December 15, 2009(CpG 1826) and an agonistic monoclonal antibody specific for
CD137 (anti-CD137, clone 3H3) against established subcuta-
neous tumors in mice.
CpG 1826 is an unmethylated oligodeoxynucleotide that mi-
mics sequences often found in bacterial DNA. It is a Toll-like
receptor (TLR) agonist that binds to TLR9 (1) found on human
B cells (2) and plasmacytoid dendritic cells (DC; ref. 3). TLR9 is
also expressed additionally in the mouse on monocytes/macro-
phages and DCs constitutively (4, 5) and reported on human
monocytes (6), neutrophils (7), and natural killer (NK) cells
(8) upon activation. Binding to TLR9 elicits cellular activation
through MyD88 to NF-κB and IFN-regulatory factor 1 and 7
(9). Triggering of these pathways results in the production of
proinflammatory cytokines including IFNs and interleukin
(IL)-12 (10). Ligation of TLR9 results in activation of immune
cells (11, 12) and increased costimulatory and antigen presen-
tation capabilities, which can lead to an enhanced adaptive im-
mune response (13, 14).
Treatment with CpG oligodeoxynucleotide alone or in com-
bination with other agents can lead to inhibition of tumor
growth in mice (15–18). Based on these findings, CpG oligo-
deoxynucleotides are also being tested in clinical trials against
cancer in humans with the first demonstrations of immune ac-
tivity (19) and tumor responses being reported (20, 21).
CD137 is expressed on the surface of activated T cells (22),
monocytes (23), NK cells (24), and DCs (25). Interaction with
its ligand, CD137L, expressed on macrophages, B cells, and DCswww.aacrjournals.org
Translational Relevance
In this study, we show eradication of established
tumors in two mouse models using a novel combi-
nation of two immunomodulating agents. The
agents have been used individually in mice and
clinical trials before, and safety was demonstrated.
However, these agents used singly, or in other com-
binations, usually have only limited antitumor ef-
fects. The current study identifies the best way of
administering this novel combination to achieve dra-
matic regression of tumors. We also describe new
insight into the mechanisms of the combination ther-
apy not previously observed. These mechanisms in-
clude potential roles for B cells and macrophages,
which may provide information for enhancing thera-
py even further. These considerations strongly sup-
port the translational relevance of this work.
Triggering TLR9 and CD137 for Cancer Therapy(26, 27), augments signals delivered through the T-cell receptor
leading to enhanced cytokine secretion, proliferation, and sur-
vival of T cells (28, 29).
Treatment with CD137 agonists has been shown to impact
on tumor growth in mice, and alone or in combination with
other immunomodulatory agents, can lead to regression of
established tumors (30–33). In addition, phase I clinical trials
using an agonistic antibody specific for CD137 are currently
under way (34).
Reasoning that a combination of agents with the potential to
generate inflammatory signals, enhance antigen presentation,
and costimulate T cells may lead to a robust antitumor immune
response, we tested their efficacy against two types of estab-
lished tumors in mice and determined the cellular and molec-
ular mechanisms involved in the antitumor responses.Materials and Methods
Cell lines and mice. MC38, a mouse colon cancer cell line, and the
renal cell carcinoma cell line, Renca (35), were maintained at 37°C
and 5% CO2 in RPMI 1640 (Invitrogen), supplemented with 10%
heat-inactivated FCS (Moregate Biotech), 2 mmol/L glutamine (JRH
Biosciences), 100 U/mL penicillin, and 100 μg/mL streptomycin (both
from Sigma).
C57BL6 and BALB/c mice were purchased from The Walter and Eliza
Hall Institute of Medical Research and from The Animal Resource
Centre. They were housed in specific pathogen-free conditions. Gene-
deficient mice were bred in the Peter MacCallum SPF Facility. Mice of
6 to 20 wk of age were used in all experiments, and experiments were
done according to The Peter MacCallum Cancer Centre Animal Exper-
imentation Ethics Committee guidelines.
Tumor growth in mice. C57BL6 mice were inoculated s.c. with 1 ×
106 MC38 tumor cells in 100 μL PBS. Treatment started 8 to 11 d later,
after randomization of mice into groups with similar average size tu-
mors. BALB/c mice were inoculated s.c. with 2 × 105 Renca cells in
100 μL PBS. Some groups received CpG 1826 (Coley Pharmaceuticals)
at 50 μg/50 μL/dose intratumorally (i.t.) every 2 to 3 d for a total of four
doses, delivered as 30 μL directly into the tumor interior, and 10 μL to
each side of the tumor. Other groups additionally received anti-CD137
monoclonal antibody (clone 3H3), generated in-house from a hybrid-
oma cell line, as originally reported in 1997 (36), at 100 μg/200 μL
PBS/dose i.p. every 3 to 4 d for a total of three doses. Some groups re-7625www.aacrjournals.orgceived saline instead of CpG, and irrelevant rat IgG2a (MAC-4, produced
in-house from European Collection of Cell Cultures hybridoma) instead
of anti-CD137 antibody as negative controls.
Tumor size was measured with calipers every 2 to 3 d. Tumor pro-
gression was also determined by survival of mice, which was defined as
time until mice became stressed or tumors were >150 mm2, at which
point they were euthanized. Gene-deficient mice were used in some ex-
periments: Rag 1, MyD88, IFNαR1, IFNγ, tumor necrosis factor α,
TRAIL, IL-12, and μMT. All mice were produced from C57BL/6 embry-
onic stem cells or crossed onto a C57BL/6 background for greater than
10 generations. Depletion of CD4+ T cells and CD8+ T cells was carried
out in some groups of mice by injection of anti-CD8 monoclonal an-
tibody (clone 53-6-72), anti-CD4 monoclonal antibody (clone GK1.5),
and control monoclonal antibody (MAC-4), which were injected i.p. at
the dose of 100 μg/200 μL PBS on days -1, 0, and 1, and every 3 to 4 d
thereafter after start of treatment. NK cells were depleted in some
groups by injection of anti-asialo GM1 (rabbit immunoglobulin, Wako
Pure Chemical Industries Ltd, Richmond); 1 mL was purchased, diluted
1/10 in PBS and 200 μL injected initially the day before start of treat-
ment, then 100 μL was injected day 0, and every 3 to 4 d thereafter.
Flow cytometry was used to assess whether depletion had occurred,
staining cells with a different clone was carried out as follows: CD4-
FITC (clone L3T4, Rm4.4, BD), CD8α-PeCy7 (clone 53-6.7, BD),
CD8β-PE (clone H15-17.2, BD), and NK1.1-APC (clone PK136, for de-
tection of NK cells in C57BL/6 mice only).
Depletion of macrophages was by treatment of mice with clodrolip
(clodronate) in PBS supplied as a 17-mg/mL stock (37). On day of in-
jection of tumor, 2 mg/200 μL clodrolip was injected i.p. to each
mouse. Thereafter, each mouse was injected twice per week with
1 mg/200 μL clodrolip i.p. for the next 2 wk.
Antibodies and flow cytometry. For flow cytometry of DC popula-
tions, antibodies used in this study were CD11c-PE (eBioscience),
MHC II (I-A/I-E)-APC (eBioscience), CD19-PeCy5.5 (eBioscience),
CD86-FITC (eBioscience), biotinylated CD45RA (BD), and streptavi-
din-PECy7 (eBioscience). MC38 tumor was injected at 1 × 106/25 μL
s.c. into the upper foot, then CpG (50 μg/20 μL) or PBS (20 μL) injected
on day 8. For DC isolation, mice were culled on day 9 at 24 h after
treatment, and draining popliteal lymph nodes were harvested. Lymph
nodes were cut up finely and digested in RPMI 1640 with 2% FCS and
1 mg/mL Collagenase IV (Worthington) for 30 min at 37°C on a
shaker. Tissues were crushed through a 70-μm sieve, rinsed and spun
at 300 g for 7 min, and resuspended in 3 mL Optiprep (Sigma; 25% v/v
with HBSS). Three milliliters of a solution of Optiprep (19% v/v) in
0.15 mol/L NaCl, 10 mmol/L HEPES, 1 mmol/L EDTA, 0.5% bovine
serum albumin (pH 7.4) were layered on top, followed by 0.5-mL layer
of FCS. The gradient was spun at 600 g for 20 min. The top interface
was collected, rinsed, and the cells were stained with a cocktail of
the above antibodies (1 μg/106 cells) in 50 μL of PBS/10% FCS for
25 min/4°C, followed by two washes in PBS/10% FCS, and analyzed
by flow cytometry using a flow cytometer (LSR, BD Biosciences).
For T-cell analysis, cells from blood, draining popliteal lymph nodes,
and tumor were stained with TCRβ-APC (BD) and CD122-PE (BD).
Tumor was processed in RPMI containing 3 mg/mL Collagenase IV
(Worthington), 30 U/mL DNase (Sigma) and 0.1 mg/mL Hyaluronidase
(Worthington), 2 mmol/L glutamine (JRH Biosciences), 100 U/mL pen-
icillin, and 100 μg/mL streptomycin (both from Sigma) for 1 h at 37°C
on a shaker, then crushed through a 70-μm sieve, were rinsed, were
spun, and were resuspended. Lymph nodes were crushed between two
forceps, then through a 70-μm sieve, were rinsed, were spun, and were
resuspended. Blood was lysed in ACK buffer, was spun, and was resus-
pended before staining.
For determining the frequency of IFN-γ–producing T cells in treated
mice, tumors were implanted s.c in the upper foot followed by treatment
10 d later. Mice were culled on day 17 after tumor inoculation, following
treatment with CpG (days 10, 12, 14, 16) and anti-CD137 (days 10, 14).
Draining popliteal lymph nodes were taken, were dissociated, and
the cells (2 × 106 cells/mL) were incubated with plastic-immobilizedClin Cancer Res 2009;15(24) December 15, 2009
Cancer Therapy: Preclinicalanti-CD3 (0.125 μg per well, 4°C overnight) in 1 mL RPMI 1640 in
48-well tissue culture plates. After overnight incubation of cells in
the presence of Golgistop, cells were harvested and stained for TCRβ
(PECy5.5, Ebioscience) and intracellular IFN-γ (APC conjugated,
Ebioscience) using a kit according to manufacturer's instructions (BD).
Microarray analysis. MC38 tumors were allowed to establish for
10 d and then injected with 50 μg of CpG 1826 i.t. After 6 h, mice were
euthanized and the tumors removed and immediately frozen on liquid
nitrogen. RNA was isolated, and cDNA was prepared and hybridized on
Affymetrix Mouse Gene 1.0 ST chips. Microarray analysis was done us-
ing R (2.6.1), BioConductor 2.1 and limma 2.12.0. Using a linear mod-
el, expression levels of the control-treated (PBS) arrays were compared
with that of the treated arrays. The Affymetrix annotation file MoGene-
1_0-st-v1.na24.mm8.transcript.csv and NetAffx were used to obtain
annotations.
Statistical analysis. For survival studies, a Log-Rank and Wilcoxon
test was used, and results were expressed as Fisher's Exact test values
(two sided). For tumor growth comparisons, two-sided P values (P2)
were determined using a Mann-Whitney test. For microarray studies,
a moderated t statistic and an adjusted P value significance of expres-
sion differences were determined for CpG-treated mice compared with
vehicle control-treated mice.
Results
TLR triggering and costimulation of T cells eradicates estab-
lished tumors. Mice were injected s.c. with the mouse colon
cancer cell line, MC38, which was allowed to establish for
8 to 10 days, by which time tumors were approximately 30
to 50 mm2. Mice then received treatment consisting of i.t. injec-
tion of CpG (50 μg in 50 μL) alone or in combination with
anti-CD137 (100 μg in 200 μL PBS i.p.). Other groups of mice
were left untreated or received i.t. vehicle (saline) alone. I.t. in-
jection was chosen because systemic administration of CpG was
found to induce toxicity at 50 μg or above per dose. Control
nontreated or vehicle-treated (PBS) mice all died before day
34 and there was no statistical difference between survival of
nontreated and saline-treated mice (P2 = 0.28; Fig. 1A). Mice
receiving i.t. CpG survived significantly longer than control
nontreated or PBS-treated mice (P2 < 0.0001) with 39% of mice
surviving long term. However, when CpG was combined with
i.p. anti-CD137, mice survived significantly longer than those
receiving CpG alone (P2 = 0.0263), with 83% of mice surviving
long term (Fig. 1A).
To determine if this combination therapy was effective
against other tumors, we investigated the efficacy against the re-
nal cell carcinoma, Renca, inoculated s.c., and allowed to estab-
lish for 8 to 10 days to reach a size of approximately 30 to 40
mm2. Again, the combination of CpG and anti-CD137 induced
significantly better tumor growth inhibition than control mice
(P2 ≤ 0.0001) or those treated with either agent alone (P2 ≤
0.0001; Fig. 1B). In addition, a large proportion (69%) of
CpG + anti-CD137–treated mice survived long term.
A proportion of contralateral tumors respond to remote CpG
and anti-CD137. Because it is not always practical to directly
inject each tumor deposit in patients, we investigated whether
injection of a “primary” subcutaneous tumor could impact on
the growth of a distant, contralateral tumor. Mice received pri-
mary tumor injection followed by a contralateral “secondary” tu-
mor 2 days later (same dose of 1 × 106MC38 tumor cells/100 μL
s.c. for both). After a further 8 days, mice received treatment con-
sisting of i.p. anti-CD137 and CpG injection in the primary tu-
mor only. All control, nontreated mice died by day 25, whereas7626Clin Cancer Res 2009;15(24) December 15, 2009treated mice survived significantly longer (P2 = 0.0011), with
50% surviving long term (Fig. 2A). Primary tumor was rejected
in five of six mice (Fig. 2B) and secondary tumor was rejected in
three of sixmice (Fig. 2C). Although three of sixmice succumbed
to secondary disease, two of the three contralateral tumors in
these mice regressed fully until day 28 after tumor inoculation,
before eventually progressing (Fig. 2C).
Cellular and molecular mechanistic contributions to tumor
eradication. To gain mechanistic insight into the tumor rejec-
tion process, we investigated the contribution of various subsets
of leukocytes. Using Rag 1-/- mice deficient in B cells and T cells,
we showed that cells of the adaptive immune system played a
role in tumor inhibition and rejection, because treatment with
CpG + anti-CD137 was ineffective in these immunodeficient
mice compared with wild-type mice (Fig. 3A). In addition, B
cells played no role in therapy because treatment was still effec-
tive in μMT-/- mice that were deficient in B cells (P2 = 0.1617
compared with wild-type mice; Fig. 3A). To better define the
types of leukocytes responsible for antitumor responses, we de-
pleted subsets by administration of specific antibodies begin-
ning 1 day before the start of treatment and continuing twice
weekly for the duration of the experiment. CD8+ T cells were
found to play a major role in tumor regression because treat-
ment in mice depleted of CD8+ T cells was ineffectiveFig. 1. CpG plus anti-CD137 causes tumor regression in mice. A,
comparison of survival in mice injected with 1 × 106 MC38 s.c. and then
treated starting on day 8 with either saline i.t., CpG i.t., anti-CD137 i.p., or
CpG i.t. plus anti-CD137 i.p. or not treated (NT ) (pool of two experiments).
Number of mice per group in parentheses. B, comparison of survival
in mice bearing 8-d old Renca tumors s.c., treated with either CpG i.t.,
anti-CD137 i.p., or CpG i.t. plus anti-CD137 i.p. or not treated (pool of
three experiments).www.aacrjournals.org
Triggering TLR9 and CD137 for Cancer Therapy(Fig. 3B). In contrast, depletion of CD4+ T cells did not affect the
outcome of therapy, demonstrating no role for these cells in
treatment-mediated tumor regression (Fig. 3C). Depletion of
NK cells, using anti–Asialo-GM1, led to no significant difference
in survival (1 of 8) of the treated group, compared with the non-
treated group (0 of 8). However, the tumor growth rate was
significantly decreased in NK cell–depleted mice compared with
nontreated mice, and was intermediate between that of the trea-
ted nondepleted group and that of the nontreated group,
tsuggesting at least a partial role for NK cells (Fig. 3D).7627www.aacrjournals.orgHaving gained some insight into cells important in tumor re-
jection, we investigated the contribution of some key mole-
cules, using a range of tumor-bearing gene-deficient mice.
Treatment inhibited tumor growth as usual in wild-type mice,
with 70% surviving long term (Fig. 4A). However, survival of
treated mice deficient in the TLR signal molecule MyD88 was
not statistically different from nontreated MyD88-deficient
mice, with only 2 of 10 mice surviving, indicating a require-
ment for this molecule (P2 = 0.4746; Fig. 4A). In addition, mice
deficient in IFN-α receptor-1 or IFN-γ all succumbed to tumors
similarly to nontreated mice (P2 = 0.3127 and >0.9999, respec-
tively), demonstrating a requirement for both type 1 and type 2
IFNs in the tumor rejection process (Fig. 4A-B).
Survival of mice deficient in the inflammatory cytokine, IL-
12, or the cytolytic protein, perforin, was significantly different
from nontreated knockout mice (P2 <0.0001 for each; Fig. 4B),
showing that the therapy still worked in the absence of these
molecules, suggesting there was no absolute requirement for
these molecules. However, a trend to accelerated tumor growth
kinetics for treated perforin-deficient compared with treated
wild-type mice (P2 = 0.0002) and lower survival of these
tumor-bearing mice suggested a partial role for perforin. In ad-
dition, there was no contribution from TNF-α, FASL, or TRAIL,
because mice deficient in these genes were still able to reject
tumors similarly to wild-type mice (data not shown).
To gain further insight into the mechanism of therapy, we in-
vestigated the effect of i.t. injection of CpG on gene expression
using DNA microarray. Analysis was done using CpG alone to
focus on this contribution, and samples were taken soon after
injection (6 hours) before significant tumor cell death. A total
of 150 genes were upregulated, and 8 genes were downregu-
lated, by >2-fold (Supplementary Table S1). Expression changes
involved genes from various pathways including immunity, in-
flammation, and cellular movement. Immune genes were par-
ticularly well represented with the greatest changes in cytokines
and chemokines. Surprisingly, increased expression of some
molecules important in downregulation of immune responses
were also seen, including endothelin, SOCS3, and PD-1 ligand.
Of particular note was the upregulation of genes associated
with macrophages/monocytes including nitric oxide synthase,
MIP-1α, MIP-2α, and CD14, and we therefore sought to deter-
mine the contribution of these cells to the therapeutic antitu-
mor effect. This was investigated using administration of
clodrolip, a cytotoxic agent (clodronate) encapsulated in lipid
vesicles that depletes phagocytic cells, chiefly macrophages, but
also a proportion of neutrophils and DCs (37). Depletion ex-
periments showed that macrophages were not required for tu-
mor regression. Indeed, tumors grew slower in mice receiving
clodrolip (for macrophage depletion; P2 = 0.0012), and treat-
ment-induced regression of similar sized tumors occurred signif-
icantly faster in macrophage-depleted mice than in nondepleted
mice (P2 = 0.008 at day 16 after tumor inoculation; Fig. 4C).
CpG and anti-CD137 treatment leads to DC and T-cell activa-
tion. Having shown the importance of CD8+ T cells in this
therapy, we more closely investigated further parameters of
the adaptive immune response. Because DCs are important in
the activation and expansion of CD8+ T cells, we first deter-
mined the effect of i.t. CpG and anti-CD137 injection on the
phenotype of DCs in tumor-draining lymph nodes. DCs were
enriched by density gradient centrifugation and flow cytometry
used to distinguish plasmacytoid DCs from other DCs, andFig. 2. Contralateral tumors respond to treatment. MC38 cells (1 × 106)
were injected s.c. into the right flank of each mouse. Another injection of
MC38 (1 × 106) was also injected s.c. on the contralateral side 2 d later to
represent a distant metastasis. Treatment with CpG plus anti-CD137 started
on day 9 after primary tumor inoculation. A, survival of mice bearing both
tumors was monitored long term after receiving both CpG and anti-CD137
or left untreated. B, primary tumor size in mice treated with both CpG and
anti-CD137 was compared with primary tumor size in other control mice
receiving no treatment. C, contralateral secondary tumor size in treatedmice
was compared with secondary tumor size in the control mice. Numbers
beside lines, number of long-term survivors/number per group.Clin Cancer Res 2009;15(24) December 15, 2009
Cancer Therapy: Preclinicaltheir activation status was determined by staining for the costi-
mulatory molecule CD86. The most striking effect of CpG in-
jection was on plasmacytoid DCs (defined as CD11c+ CD45RA+
MHCII+ CD19-), with increases in both the proportion of CD86+
cells and in the level of CD86 expression (Supplementary Fig. S1).
An increase in CD86 expression was also observed on nonplas-
macytoid DCs, although this change was less pronounced than
that observed on plasmacytoid DCs (data not shown). These
data suggested that DCs acquired a greater ability to stimulate
T cells following administration of CpG and anti-CD137.
To determine the effect of treatment on T-cell frequency,
numbers, and activation, blood and lymph nodes were taken
from mice at 7 days following treatment (day 17 after tumor
inoculation) and analyzed using flow cytometry on dissociated
tissue. Day 7 was chosen because preliminary experiments
showed that changes to immune parameters including lymph
node size and T-cell numbers were most evident at this time.
The frequency of activated T cells (CD122+) was significantly
increased in tumor-draining lymph nodes following anti-
CD137 treatment alone (P2 = 0.002; Fig. 5A), but was actually
decreased following treatment with CpG alone (P2 = 0.002).
However, when anti-CD137 and CpG were used in combina-
tion, the frequency of activated T cells was further increased
above all other groups (P2 = 0.004 compared with anti-
CD137 alone). Interestingly, although the frequency of activat-
ed T cells increased, there was no significant change in total
number of T cells per draining lymph node following com-
bined treatment with CpG and anti-CD137 (Fig. 5A). However,
administration of anti-CD137 alone did result in a significant
increase in the number of T cells in draining lymph nodes (P2 =
0.026), whereas administration of CpG alone led to a signifi-
cant decrease in T-cell numbers (P2 = 0.004; Fig. 5A).7628Clin Cancer Res 2009;15(24) December 15, 2009When the total numbers of leukocytes (CD45+) per draining
lymph node were considered, treatment with anti-CD137 alone
or CpG alone resulted in increased numbers of total leukocytes
(Fig. 5B), but treatment with both agents did not lead to in-
creased leukocyte numbers. Similar to the results in lymph
nodes, the frequency of activated T cells in the blood was sig-
nificantly increased in mice receiving both agents (six mice per
group analyzed individually; Fig. 5B).
To determine if tumors contained an increased frequency of
T cells, tumors were removed from mice following treatment,
were enzymatically disaggregated, and were subjected to flow
cytometry. The frequency of tumor-infiltrating T cells in mice
treated with both anti-CD137 and CpG increased by ∼3-fold
over mice receiving PBS and control immunoglobulin treat-
ment (Fig. 5C). In addition to the effect on T-cell frequency,
we also determined the effect of treatment on T-cell function.
Cells from tumor-draining lymph nodes were incubated with
immobilized anti-CD3 and the percentage of IFN-γ–producing
T cells were determined. Treatment with CpG and anti-CD137
generated greater numbers of T cells expressing IFN-γ than con-
trol-treated mice or those receiving single agents (P2 = 0.015;
Fig. 5C). These experiments, taken together with the absolute
requirement for CD8+ T cells, suggested that treatment re-
sulted in an enhanced T-cell response that contributed to tu-
mor regression.
Administration of CpG and anti-CD137 induces immunologic
memory. To determine if combined CpG and anti-CD137 ther-
apy could lead to immunologic memory, survivors (>48 days)
were rechallenged with 1 × 106 MC38 cells s.c., and tumor
growth and survival were monitored. Tumors grew progressively
in naïve nontreated mice, demonstrating the viability of the
tumor cells used, but tumors, after initially growing for up toFig. 3. Response to treatment in gene-deficient mice and mice depleted of lymphocyte subsets. MC38 cells (1 × 106) were injected s.c. into various
gene-deficient mice or mice depleted of different cell subsets, and then treated with CpG plus anti-CD137 starting on day 8 or 9, or not treated, and tumor size
and survival monitored. Growth curves were stopped when the first mouse died in each group (tumor size, >100 mm2). A, in experiments with gene-deficient
mice; ◊, nontreated mice; △, CpG + anti-CD137–treated mice. In other experiments, mice were depleted of cell subsets using (B) anti-CD8, (C) anti-CD4,
or (D) anti–asialo-GM1 (αAS) or control immunoglobulin (MAC-4). Tumors in all nontreated mice continued to grow and all these mice were eventually
euthanized when tumors reached 100 mm2 in size. Numbers beside lines, number of long-term survivors/number per group.www.aacrjournals.org
Triggering TLR9 and CD137 for Cancer Therapyday 13, completely regressed in 12 of 13 rechallenged mice,
which went on to survive long term (Fig. 6A). This showed the
presence of immunologic memory in mice that had survived
following CpG + anti-CD137 after an initial tumor challenge.
To determine potential roles of various molecules and cells in
the induction of immunologic memory, we also rechallenged a
range of gene-deficient mice that had rejected a primary tumor
challenge in response to combined CpG and anti-CD137 treat-
ment. Although antitumor immune memory was observed in
TRAIL-/- and TNF-/- mice with all mice protected from rechal-
lenge (data not shown), resistance to tumor rechallenge was not
shown in B cell–deficient μMT mice (Fig. 6B-C), suggesting a
role for B cells in the induction of immunologic memory me-
diated by CpG and anti-CD137.Discussion
This study aimed to determine the antitumor effect of com-
bining the inflammatory and immune stimulatory capabilities
of a TLR agonist with the costimulatory capacity of an agonistic
anti-CD137 antibody. Treatment resulted in increased survival
of a large proportion of mice bearing either of two established
solid tumor types. The antitumor properties of this combina-
tion of immunostimulatory agents has not been reported be-
fore. This relatively simple treatment regimen of only two
agents led to complete regression and long-term survival of a
large proportion of mice.
CpG was delivered i.t. because systemic administration
(either i.p. or i.v.) was found to be toxic above 50 μg per dose,7629www.aacrjournals.orgwith a large proportion of mice dying. The use of 50 μg or less of
CpG systemically was ineffective at inducing tumor regression
(data not shown). In these experiments, CpG and anti-CD137
were administered concurrently, resulting in tumor rejection in
a large proportion of mice, but it would be of interest perhaps in
future to determine if even better therapeutic outcomes could be
afforded by different regimens involving sequential use of CpG
and anti-CD137.
Because i.t. injection of all tumor masses in patients is usually
not practical, we tested the effect of i.t. injection on a distant
tumor implanted contralaterally to the injected tumor. Injec-
tion of one tumor only resulted in rejection of both tumors
in 50% of mice, which supported the physiologic relevance of
this approach. It is considered likely that rejection of contralat-
eral tumors was mediated, at least partially, by the immune re-
sponse generated from injection of the primary tumor, because
only small amounts of CpG (<50 μg) probably gained access to
the circulation and this was considered too little to induce com-
plete tumor regression based on previous studies. Although dis-
tant subcutaneous tumors could be inhibited using this
treatment, it is not clear whether tumor metastases at other his-
tologic sites or whether spontaneously arising tumors could be
similarly impacted, and it would be of interest to address these
issues in future studies.
Mechanistically, CD8+ T cells and type I and II IFNs were
shown to play a crucial role in tumor regression. Therapy was
also negatively affected following cell depletion using anti–
asialo-GM1, suggesting a role for NK cells. However, the pres-
ence of asialo-GM1 on some activated T cells makes a strict inter-
pretation of these data difficult. Consistent with the need forFig. 4. Response to treatment in
various gene-deficient mice and in mice
depleted of macrophages. MC38 cells
(1 × 106) were injected s.c. into various
gene-deficient mice or mice depleted of
macrophages using clodrolip as
detailed in Materials and Methods,
followed by treatment with CpG plus
anti-CD137 starting on day 8 or 9
after tumor inoculation, or not treated.
Tumor size and survival monitored.
Growth curves were stopped when the
first mouse died in each group.
Numbers beside each curve, number
of long-term survivors/number of mice
in group.Clin Cancer Res 2009;15(24) December 15, 2009
Cancer Therapy: PreclinicalCD8+ T cells for effective therapy, there was a significant increase
in circulating activated T cells following treatmentwith bothCpG
and α-CD137 compared with other treatments (P2 = 0.002).
Anti-CD137 alone also resulted in a significantly higher frequen-
cy of circulating activated T cells above control-treatedmice (P2 =
0.002), but this alone was not sufficient to impact to any great
degree on MC38 tumors. The contribution of CpG to the treat-
ment effects may have been in an increased ability to generate
tumor-specific T cells and/or in the production of chemokines
and an immune stimulatory environment within tumors.
Indeed, CpGmay have impacted onmyeloid-derived suppres-
sor cell or regulatory T-cell numbers or function, which could
have led to enhanced antitumor immunity. However, there
was no significant effect of treatment on gene expression levels
of FoxP3 or CD11b, but it would be of interest to investigate
these questions in future experiments. In addition, therapy
may have impacted on the function of endothelium within the
tumor microenvironment, and because endothelial cells play a
crucial role in the access of immune cells into tumor, it would
be interesting to perform analyses in future to determine changes
in endotheial morphology, phenotype, and function.
In addition to 3H3, enhanced T-cell responses have also been
observed for other agonist anti-CD137 antibodies including 2A,7630Clin Cancer Res 2009;15(24) December 15, 20093E1, and 1D8, and although a direct comparison of all has not
been done, tumor inhibition has been reported with all of these
(36, 38). Whether comparable activity of each antibody in com-
bination with CpG could be achieved is not known at this stage.
Interestingly, B cells were not required for therapy-induced
tumor rejection despite their large numbers and expression of
the receptor for CpG, TLR9. Nevertheless, antitumor immuno-
logic memory was compromised in B cell–deficient mice, sug-
gesting a role for B cells in the establishment of T-cell memory.
B cells have previously been reported to play a role in promot-
ing T-cell memory in some antimicrobial responses (39–41),
but not in others (42). However, their role in memory induc-
tion against malignancy has not been previously described.
It is not clear at present whether B cells played a direct or in-
direct role in promoting T-cell memory in this system. TLR9 li-
gation can induce proliferation of B cells and endow them with
enhanced antigen-presenting capabilities (43), which may con-
tribute to T-cell memory. B cells can produce antibody and also
secrete a range of cytokines in response to TLR ligation, includ-
ing IFN-γ, IL-6, IL-10, and IL-12 (44), some of which may assist
in the generation of T-cell memory. In addition, B cells have
been reported to be important for normal development of
marginal zones and T-cell zones of the spleen, but not thoseFig. 5. T-cell expansion and activation
in response to CpG + anti-CD137. MC38
cells (1 × 106) were injected s.c. into
the upper foot of C57BL6 mice, which
were then treated with CpG plus
anti-CD137 starting on day 10. The
draining popliteal lymph node and
blood were taken on day 17 and
analyzed using flow cytometry. A, the
frequency of activated T cells
(expressing CD122) in draining lymph
nodes and the absolute number of
T cells per lymph node. B, the absolute
number of leukocytes (CD45+) per
lymph node and the frequency of
activated T cells (CD122+) in the blood
(six mice per group). C, the frequency of
T cells in tumors and lymph nodes of
mice receiving the treatments listed.
Tumors were taken on day 20 after
tumor inoculation (results are
representative of two experiments).
Draining lymph nodes were taken on
day 17 and the frequency of T cells
expressing IFN-γ in response to
stimulation with anti-CD3 was
determined.www.aacrjournals.org
Triggering TLR9 and CD137 for Cancer Therapyof the lymph nodes (45, 46). These structural differences could
account for lower T-cell memory despite having no effect on the
primary immune response. B cell–deficient mice have also
sometimes been reported to have reduced numbers of DCs in
the spleen, which could also explain why there is reduced mem-
ory but sufficient primary response in CpG + α-CD137–treated
μMT mice (46). It will be of interest to determine the relative
importance of these components in future experiments. It is al-
so interesting to speculate whether reduced immunologic mem-7631www.aacrjournals.orgory plays a role in inhibition of some autoimmune conditions
using the B cell–depleting antibody Rituximab.
The presence of increased expression of nitric oxide synthase
within tumors after only 6 hours suggested that CpG induces a
rapid myeloid cell effector response in tumors. The participa-
tion of myeloid cells was also supported by the increased ex-
pression of genes associated with myeloid cell recruitment
including MIP-1α, MIP-2α, and CD14. However, depletion ex-
periments showed that macrophages were not required for tu-
mor regression. Indeed, tumors appeared to grow slower in
macrophage-depleted mice, and treatment-induced regression
occurred significantly faster in macrophage-depleted mice than
in nondepleted mice. Indeed, 100% of mice rejected their tu-
mor after treatment following macrophage depletion. This sug-
gested that MC38 tumors normally contained a population of
M2 macrophages that produce an immune suppressive micro-
environment (47), which enhanced tumor growth, and that
depletion of these macrophages resulted in a reduction of sup-
pression and enhanced therapeutic effect of combined CpG and
anti-CD137 treatment. In addition, macrophage depletion with
clodrolip has also been previously shown to deplete resident
macrophages in other tissues including spleen, liver, and kidney
(37). In the spleen, the red pulp F4/80+ macrophages as well as
metallophilic and marginal zone macrophages are depleted,
whereas T cells, B cells, and follicular DCs are not affected. This
might influence the immune response after treatment. However,
it is not clear at this time if the relative depletion of macrophages
and other myeloid cells observed in previous studies extends to
the current model. This is the first report of enhanced immu-
notherapy after macrophage depletion using clodrolip.
The microarray studies represented the first description, to
our knowledge, of gene expression of mouse tumors in vivo in
response to local CpG treatment. These studies determined that,
in addition to upregulation of many immune stimulating
genes, some genes associated with immune suppression were
also upregulated, including endothelin (inhibits lymphocyte
migration), PD-1L (induces T-cell death), and SOCS3 (sup-
presses cytokine responses). However, it is likely that the overall
balance of immune activity initiated by CpG injection was
weighted toward stimulation of the immune response.
Interestingly, CpG induced CD137 upregulation in tumors. It
is not clear at this time if this was expressed by leukocytes or
other cells. CD137 has been shown to be upregulated on endo-
thelial cells within inflamed tissue, and postulated to enhance
the migratory capacity of monocytes (48). It is possible that
CpG-mediated upregulation of CD137 within tumors com-
bined with agonistic anti-CD137 cooperated directly within tu-
mor tissue to induce antitumor effects.
Of interest were the increases in the frequency and number of
activated T cells in the blood. In the present study, administra-
tion of anti-CD137 alone or CpG alone resulted in enlarged
lymph nodes and increased numbers of leukocytes per lymph
node, primarily T cells, and B cells, respectively, as observed
previously in nontumor–bearing mice (49, 50). However, we
report here for the first time that combined administration of
anti-CD137 and CpG resulted in reduced numbers of leuko-
cytes per node compared with either agent alone. Nevertheless,
increased numbers of activated T cells were mobilized into the
blood following the combination treatment.
From the above study, the most likely reason for the relative
effectiveness of combined anti-CD137 and CpG treatment isFig. 6. CpG plus anti-CD137 elicits a memory response, but not in mice
deficient in B cells. Naïve mice or those surviving long term after CpG +
anti-CD137–mediated MC38 tumor rejection were injected with MC38 cells
(1 × 106) s.c. and tumor progression monitored. A, survival of naïve C57BL/6
mice (BL/6) or surviving C57BL/6 mice after injection of MC38 cells. △,
naïve mice receiving CpG + anti-CD137 8 d after tumor inoculation. ◊, naïve
mice nontreated after tumor inoculation.▴, long-term surviving C57BL/6mice rechallenged with MC38 on day 0. B, growth of tumors following
MC38 cell injection into long-term surviving C57BL/6-μMT mice (▪), or
naïve C57BL/6 wild-type, followed by no treatment (▴) or CpG/anti-CD137treatment (⧫). C, survival of mice after challenge with 1 × 106 MC38 cells s.c.
⧫, naïve C57BL/6 mice treated with CpG + anti-CD137.▴, naïve C57BL/6mice nontreated. ▪, long-term surviving C57BL/6-μMT mice. Experiment
was performed twice with similar results.Clin Cancer Res 2009;15(24) December 15, 2009
Cancer Therapy: Preclinicalthe induction and amplification of both innate and adaptive
immune components. I.t. injection of CpG led to dramatic
changes in the tumor microenvironment involving upregulated
expression of many genes associated with immune activation.
Subsequent DC maturation and T-cell activation were also ap-
parent, which may have played an important role in tumor re-
jection. Using combinations of immune-modulating agents
satisfying multiple requirements against tumor, reminiscent of
responses against infectious disease, may provide important ad-
vances for improved therapies for cancer.7632Clin Cancer Res 2009;15(24) December 15, 2009Disclosure of Potential Conflicts of Interest
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